Upload
vanhuong
View
214
Download
0
Embed Size (px)
Citation preview
15 May, 2017
Pullman Shanghai South
Shanghai
S h o w c a s e
Fenglin Forum
http://www.sebpchina.com
I n v e s t m e n t
P a r t n e r i n g
I n n o v a t i o n
Sino-Euro BioPartnering (SEBP) is an annual conference which provides a cost-effective and tailor-made partnership platform for European and other international SMEs to partner with local companies and investors.
SEBP was first launched by G-Med Consulting, Bioclouds, Biowin Lyonbiopole and Juke Science Park in 2013 in Shanghai. Since then, the organizers have successfully organized four conferences, and supported numerous of industry leaders and investors. The organizers offer pre-selection, onsite support and follow up services for European and US participants and have established strong network with bioclusters, academia, hospitals, industry and the investment societies.
Biotech, Pharma & Medtech
Industry Trend and Insight Investment
Guide in Europe & US
Europe & US SME Showcase
Customized Partnering Platform
Academic - Hospital - Industry
15th May, 2017 Pullman Shanghai South
SAVE THE DATE!
http://www.sebpchina.com
Partnership: Research – Clinic – Business – Investment
SEBP2017Agenda
Sino-Euro BioPartnering 2017
15th May, 2017 Monday
Site:Pullman Shanghai South
08:00--09:00 Registration
09:00--09:30 Opening
Address by Xuhui MayorAddress by Dr. Ioana Kraft ,General Manager , European Union Chamber of Commerce in ChinaAddress by Dr. Filippo Belardelli, Vice President, ALISEI bioXclusters China Gateway signing ceremony
09:30--10:30 Plenary
09:30-09:50Keynote 1: “Opportunities and Challenges of the future biomedical industry under the new medical policy in China” by Mr. Mingde YU, Chairman, China Pharmaceutical Enterprises Association
09:50-10:10 Keynote 2: “Precision Medicine in Drug Discovery” by Dr. Mingqiang ZHANG, Vice President of Amgen’s Asia R&D Center
10:10-10:30 Keynote 3: “The Successful Cross Boarder Partnership in China” by Mr. Valtero Canepa,General Manager, JV Bracco Sine Pharmaceuticals
10:30--10:50 Coffee break
10:50--11:10 Presentation
Presentation: “The Fenglin BioMedical Center" by Ms. Daisy TAO, Executive Director, Fenglin BioMedical Center
Presentation: “The bioXclusters meta-cluster” by Mr. Fabrizio Conicella, General Manager, Bioindustry Park Silvano Fumero S.p.A, bioXclusters representative
11:10--12:00 Showcase I Session I (3 projects)Moderator: Mr. Ronghui GAO, Managing Director, Fenglin BioMedical Center
12:00--13:00 Lunch Lunch and network
Panel Discussion I
Panel discussion 1: “How can innovation improve precision medicine?” Moderator: Dr. Mingde XIA, Senior Director, J&J Innovation Center, Shanghai
13:00--13:40
Ke Hua Bio-EngineeringLide Biotech3S Bio Inc. WuXi AppTec Lv Ye Pharma
13:40--14:40 Showcase IISession II (5 projects)Moderator: Mr. Brett Johnson, CEO, OneMed Market
14:40--14:55 Coffee break
http://www.sebpchina.com
Partnership: Research – Clinic – Business – Investment
SEBP2017Agenda
Sino-Euro BioPartnering 2017
15th May, 2017 Monday
Site:Pullman Shanghai South
14:55--15:40 TopicPanel Discussion II
InvestmentPanel discussion 2: “Cross border partnership and investment opportunities”Moderator: Mr. Fabrizio Conicella, General Manager, Bioindustry Park Silvano Fumero S.p.A, bioXclusters representativeRoche DiagnosticsXin Hua MedicalSinopharm SanPower GroupVirtus Inspire Capital
15:40--17:10 Showcase IIISession III (6 projects)
Moderator: Dr. Jiong ZHANG, General Manager, Shanghai Juke Biotech Park
17:10--17:20 Closing Summary
-------- Invitation Only-------
16th May, 2017 Tuesday
Site: Fenglin International Plaza
09:00--09:05 Opening Mr. Yinfei WU, President, Fenglin Life Healthcare Group
09:05--09:20 Keynote: “Overview of China Biomedical Industry” by Ms. Tina HOU, Associate Partner, McKiensey & Co.
09:20--10:20
Hopsital Introduction
Zhongshan Hospital (Affiliated to Fudan University Medical College)No.6 People's Hospital (Specialty on Diabetes and Othorpedics) Shanghai Xuhui Central Hospital
10:20-10:35 Coffee break
10:35--11:05 Panel
Topic: Clinical trial and registration in China
Moderator: Mr. Ronghui GAO, Managing Director, Fenglin BioMedical Center
Quintiles IMS
Han Kun Law Office
Mid-Link
JyTon
11:05--11:35 Company introduction: Shanghai Pharm, Yangzi River Pharm, Comermy Plc
11:35--13:00 Lunch Lunch and network 13:00--13:30
VisitVisit Fenglin BioMedical Center
13:30--14:30 Visit Shanghai Institute of Organic Chemistry, CAS 15:00--16:30 Visit Shanghai Xuhui Central Hospital
17:00--17:10 Closing Summary
http://www.sebpchina.com
A TAILORED PLATFORM FOR COLLABORATION
MEET WITH THE RIGHT LOCAL PARTNERS| Some major participants in 2017
Hospitals & Institutes
Pharmaceuticals
Medical Device Companies
CROs
Consulting
ProjectsCountry Sector Summary Interest
Germany IVD
Company has developed a diagnostic method, which determines for individual cancer patients the optimally effective drug therapy taking into account the individually characteristic tumor properties. Clinical trial for breast cancer successfully completed, clinical trials for colon, gastric and ovarial cancer: recruiting finished。
Funding & Partnership
Switzerland Medical service
VR based system for rehabilitation. The solution is a networkable bionic training technology - consisting of software, cloud based applications and robotic hardware with a targeted focus on (re)- establishing and maintaining mobility, independence in activities of daily living and quality of life. Test market includes 30 hospitals, rehabilitation and medical sports institutions, where the devices administer 60’000+ training sessions yearly, on 3’000+ users, with100+ new users per week
Funding & distributor
Switzerland Nutraceutical
The company discovers and provides innovative, high-value, sustainable ingredients, with an emphasis on health, wellness and nutrition. One key product stilbenoid with anti-inflammatory and antioxidant properties, has been shown to have beneficial effects on bone loss in two clinical and numerous preclinical studies.
Funding & partnership
UK IVD
Early cancer detection by using detecting autoantibodies in blood. Broad IP protection of cancer autoantibodies for Dx applications. Lung cancer test has demonstrated superior performance in 10,000 patient study.Test can detect cancer up to 4 years earlier than other methods.Utility as screening assay for high-risk individuals (smokers)Tests for liver and ovarian cancers in development. Commercially available in the U.S. (CLIA lab) and Europe (CE). 125,000 commercial tests sold to date
Funding & partnership
Portugal Pharmaceutical
Company specialist expertise in the process chemistry to address the complex issues associated with the development and production. The company provides Contract Manufacturing Services on: Drug Substance Particle Engineering Drug Product Proprietary Product Licensing: dermatology, ophthalmology, respiratory
Funding & distributor
US Medical Device
Life Care Magnetics LCM-1510k clearance: “to generate deep heat within body tissues for the treatment of medical conditions…”•Next Generation Aesthetic Medicine Device•Novel energy system for heat based aesthetic therapy•Treats deep tissues without damaging skin
Funding & partner
Germany Drug DeliveryThe company is the leader in transdermal therapy systemsand oral thin films. As a B2B partner to the pharmaceutical industry, the company offers solutions at all stages of drug development.
Co-development partner
US Biotech
A medical technology company engaged in cellular therapies and tissue engineering, with a focus on bone, skin, and cartilage regeneration. The company develops and processes biologic allograft products. The company is an emerging precision medicine leader in the field of cellular therapies and tissue engineering, with a focus on bone, skin, and cartilage regeneration
Licensing & distributor
US Biotech
The company is paving the way for the development of advanced gene-editing medicines to treat HIV. Its approach made use of the gene editing technology to locate the HIV-1 DNA in the T-cell, and edit the nuclease enzyme. This led not only to eradication of the virus, but perhaps more significantly, a shield against reinfection.
Funding & distribution
US PharmaceuticalThe company has received FDA approval of an oral, extended-release tablet with abuse-deterrent properties, creating the potential for a large-scale reduction in overdoses connected with prescription opioid abuse.
Distribution
ProjectsCountry Sector Summary Interest
US IVD
The company focuses on unmet cancer diagnosis and treatment needs. Specifically, the company has developed a blood test, to be used in the early detection of breast cancer in women with dense breast tissue whose cancers are missed 50% of the time. Beyond breast cancer, the company is also involved in research aimed at treating pancreatic cancer.
Funding & Partnership
US Medical Device
Next Generation Aesthetic Medicine Device. 510(k) FDA clearance for treatment of numerous tissue conditions. -1st-Revenue & near-term revenue opportunity, extensive follow on product pipeline: •Novel energy system for heat based aesthetic therapy•Treats deep tissues without damaging skin•Advantages over RF and ultrasound
Funding & distributor
US Medical Device
Company provides cutting edge targeted localized radiation, with proprietary unidirectional gold shielding. Commercially available• First in man 2013• Prostate, colorectal, pelvic region, head and neck,pancreatic cancers• 96% less radiation to surrounding health tissue• Zero radiation related toxicities• Simple, repeatable, safe
Funding & distributor
US Medical Device
The company leverages academic bioengineering, surgical expertise, micro engineering manufacturing and nano technology to provide the modern solution for the vexing problem of glaucoma. Nonclinical and animal tests show the company’s device, implanted through the eye’s surface, halts the progression of glaucoma, which can cause blindness. The device, which houses nano-engineered flow channels to shunt fluid from inside the eye to reduce pressure that damages the optic nerve, is the thickness of about 1½ human hairs.
Funding
US Biotech
The company is developing innovative tissue regeneration products from biologic sources for chronic wounds, as well as for hernia and joint repair. The company’s first product using its bridge tissue regeneration technology, a collagen matrix that heals chronic skin wounds faster compared to other skin substitutes.
Funding & distribution
US Biotech
The company is a regenerative medicine company, made a discovery that growing newborn skin cells under embryonic conditions of low oxygen and suspension, they rapidly become multi-potent stem cells. They secrete soluble and insoluble materials that are very embryonic that are able to stimulate stem cells throughout the body. We collect both of the products simultaneously. The lead product is an injectable, and two trials with excellent safety and efficacy
Funding & partner
http://www.sebpchina.com
Sponsorship Packages
Platinum Diamond Gold Silver
RMB 200,000 RMB 100,000 RMB 50,000 RMB 20,000
Registration
Free passes 10 5 3 3
Panel discussion
Panelist yes yes - -
Showcase yes yes - -
Presentation slot 1 1 1 -
Booth and logo display
Booth* yes yes - -
Logo on name tag yes yes yes -
Logo on brochure yes yes yes -
Logo on backdrop yes yes yes -
Logo on website yes yes yes yes
Promotion
Roll up poster 2 1 1 -
Advertisement on brochure One page One page One page Half page
Leaflet in bag yes yes yes -
Partnering
Prearranged meeting yes yes yes yes
Project follow up
Project information yes yes - -
SEBP2017Sponsorship
http://www.sebpchina.com
A TAILORED PLATFORM FOR COLLABORATION
| Previous Chinese participants
| Previous European participants
SIMPLY MEET WITH THE BESTS
SINOPHARM • WISON • FOSUN PHARMA • KEHUA • BIOMABS • DIAN DIAGNOSTICS • CP GUOJIAN • SUNDIA • UPPER BIOTECH • FRONTAGE • SHENZHEN TIME BOLE • HISUN PHARMA • HD BIOSCIENCES • SHANGHAI PHARMA • 3SBIO • WUXI APPTEC • SHANGPHARMA • MINDRAY • TIGERMED • NUOKANG BIOPHARM • T-MAB • FOUNTAINVEST PARTNERS • HUA MEDECINE • AB MART • ORBIMED • MEDICILON • WALVAX • MICROPOT • OMAHA CAPITAL • SHANGHAI BIOCHIP • BAYCITY CAPITAL • DAAN GENE • BSK VENTURES • ASCENTAGE PHARMA • WONDFO • HUA PHARMA • GENOR BIOPHARMA • YANGTZE RIVER PHARMA • PIONEER PHARMA • LUYE PHARMA • KEYBAY • SIMCERE • HENGRUI MEDICINE • OSMUNDA • BEIXING CAPITAL • YUYUE • CHAI TAI TIANQING PHARMA • CROWNBIO • DT CAPITAL • EDDINGPARM • KINGMED DIAGNOSTICS • MORNINGSIDE • PHARMALEGACY • QIMING VENTURE • HENLIUS BIOTECH • ZERUN BIOTECH • CHINA GRAND • TASLY • WEGO • GREATER PACIFIC CAPITAL • FARMASINO • CHINA GRAND • FOSUN DIAGNOSITICS • JIUZHOU PHARM …
• Distributors• Pharma• Investors
• Medtech / IVD• CMO/CRO• Biotech
http://www.sebpchina.com
EUROPEAN AND US SME FOCUS
| Key topics:
|Showcase:
“Opportunities and Challenges of the future biomedical industry under the new medical policy in China”
LINK
“I attended SEBP 2013 in Shanghai: I had a very positive impression. In my opinion, it is the right place to meet the Chinese scientific community, to share opinions and business opportunities, which must then be consolidated in several separate meetings. However, the proactive and informal atmosphere is very productive, and is a great facilitator for the first contacts between different cultures and business styles. I consider the participation to SEBP a great opportunity and the right investment for companies willing to explore potential partnerships into China.”
Dr. Domenico CriscuoloCEO Genovax (Italy)
“SEBP is a specialized partnering fair selecting specific spotlight topics of interest and which provides unique opportunity to share not only China market insights but also European biotech and medical company’s development and commercial focus. We did attend the conference several time, presenting our new products and technologies to Chinese potential partners specially during the roadshow. These presentations were often followed by B2B discussions and did initiate business opportunities. We do appreciate the conference and wish great success in the following years.”
Dr.Thierry Leclipteux CEO Coris BioConcept (Belgium)
“Cross border partnership and investment opportunities”
About twenty innovative companies from Europe, US and China will present their projects and business interests in drug development, biotech, IVD and medical devices sectors; Over 300 attendees from the industry and investment community will attend the conference
“The precision medicine impact to the global pharmaceutical industry development”
“How can innovation improve precision medicine?”
“Precision medicine practice in the cancer treatment”
http://www.sebpchina.com
REGISTRATION
[email protected] look forward to seeing you at SEBP2017!
Partners
Early Bird(before 30th April)
Regular(after 30th April)
On site(15th May) Description
Conference pass
m Industry, Investor, Services350 Euros *
OR2600 RMB
400 Euros*OR
3000 RMB3500 RMB***
Conference pass gives access to keynote speeches, panel discussions, showcase and partnering sessions. The conference also provides simultaneous translation, buffet lunch & coffee break
m Academia, Organisation300 Euros*
OR2200 RMB
350 Euros*OR
2600RMB
Company presentation
q Presentation Subject to application**
Subject to application** NA
Company will be given 10 minute slot to present its company (Each slot is limited for one company)
* per person ** per company (in addition to registration fee)*** Price per person, payable in RMB onlyTo enjoy the early bird rate, please register and arrange the payment before 16th of April.
Please register: www.sebpchina.com
http://www.pullman-zx.com/
Room (RMB) Free
Superior King Room 900 1 Breakfast and Internet
1,000 2 Breakfast and Internet
Superior Twin Room900 1 Breakfast and Internet
1,000 2 Breakfast and Internet
Pullman Shanghai South HotelHotels combining lifestyle and design, for business and leisurePullman Shanghai South is an international upscale business hotel, situated in ZStar Plaza in the new CBD of Shanghai Xuhui District with easy access to Shanghai South Railway Station and Shanghai National Convention & Exhibition Center. The hotel has 333 contemporary rooms and suites, an executive lounge, spa, gym and indoor swimming pool. It has 3 restaurants and 2 bars and meeting facilities that include a 1300sqm ballroom and 7 function rooms.